Clinical trial
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem…
NCT00310037 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00310037 |
|---|---|
| Title | Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma |
| Official title | A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mantle Cell Lymphoma |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 151 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2013 |
| Completion | Jun 1, 2022 |
| First posted | Apr 3, 2006 |
| Last update posted | Oct 28, 2025 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: